Appili Therapeutics Inc.
APLIF
$0.026
-$0.002-7.14%
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 850.20K | 498.60K | 247.10K | 247.10K | 0.00 |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 850.20K | 498.60K | 247.10K | 247.10K | 0.00 |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 850.20K | 498.60K | 247.10K | 247.10K | 0.00 |
| SG&A Expenses | 2.99M | 3.63M | 3.78M | 3.87M | 3.56M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 7.06M | 7.08M | 6.64M | 6.59M | 6.25M |
| Operating Income | -6.21M | -6.58M | -6.39M | -6.35M | -6.25M |
| Income Before Tax | -3.91M | -5.71M | -6.28M | -6.95M | -7.62M |
| Income Tax Expenses | 50.20K | 70.80K | 27.90K | 26.90K | 21.50K |
| Earnings from Continuing Operations | -3.96 | -5.78 | -6.31 | -6.97 | -7.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.96M | -5.78M | -6.31M | -6.97M | -7.64M |
| EBIT | -6.21M | -6.58M | -6.39M | -6.35M | -6.25M |
| EBITDA | -6.20M | -6.57M | -6.39M | -6.34M | -6.24M |
| EPS Basic | -0.03 | -0.05 | -0.05 | -0.06 | -0.08 |
| Normalized Basic EPS | -0.02 | -0.03 | -0.03 | -0.04 | -0.05 |
| EPS Diluted | -0.03 | -0.05 | -0.05 | -0.06 | -0.08 |
| Normalized Diluted EPS | -0.02 | -0.03 | -0.03 | -0.04 | -0.05 |
| Average Basic Shares Outstanding | 484.93M | 484.93M | 484.93M | 454.71M | 404.76M |
| Average Diluted Shares Outstanding | 484.93M | 484.93M | 484.93M | 454.71M | 404.76M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
